Neurology News

A clinical-stage biopharmaceutical company has announced positive topline data from a study evaluating a novel, oral 5-HT2C receptor superagonist for seizures associated with developmental and epileptic encephalopathies.

In a cohort of older adults, those with the highest percentage of high-density lipoprotein cholesterol had a 27% higher risk of incident dementia, with the risk higher for those aged 75 years and older, according to a study.

Oragenics Inc. has announced the completion of its acquisition of assets related to Odyssey Health Inc., including its proprietary neurological drug therapies and technologies.

Among patients with obstructive sleep apnea, sleeping less than 7 hours was linked to a heightened risk for all-cause mortality, according to results of a cohort study published in JAMA Network Open.

Nipocalimab showed evidence of dose-dependent, statistically significant symptom reductions in patients with generalized myasthenia gravis, while remaining generally safe and well-tolerated, in a phase 2 trial.

A neurotech company has announced an agreement with a radiopharmaceutical firm for the rights to manufacture an investigational imaging biomarker used in PET scans to assess the status of amyloid plaque in the brain.

When choosing a structure for a practice, you are making two choices: what legal structure to choose and which tax treatment to select.

The Residency to Retirement resource center offers insightful and innovative strategies to help physicians reduce taxes, protect assets, invest wisely and build wealth during all phases of their careers.

Asking about sleep habits during routine visits can help primary care physicians address cognitive decline among aging patients, according to experts.

Healio Neurology looks back at the most-viewed stories throughout the year. Highlights include the FDA’s approval of Leqembi to treat Alzheimer’s disease and the regulatory body’s clearing of a blood test for concussions.